Hepatitis
Drug research and approvals for hepatitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 258 studies of hepatitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 131 drug trials for it since 2013, FDA has 14 approved and 22 open orphan designations naming it, and the EU has 26 authorised medicines for it.
- Recruiting worldwide: 258
- Trials authorized in Canada: 131
- FDA orphan approvals: 14
- EU medicines: 26
Recruiting Now
Newest start dates first, of 258 recruiting on ClinicalTrials.gov ↗- A Trial of Inebilizumab in Participants With Autoimmune HepatitisNCT07598825 · Phase 3 · Amgen · starts Dec 18, 2026
- A Trial to Evaluate the Efficacy and Safety of WGc0201 in Patients With Chronic Hepatitis B Virus InfectionNCT07051187 · Phase 1 · Jiyan Liu · starts Dec 1, 2026
- HIV/HBV/HCV Triple Screening in Primary CareNCT07031219 · Not applicable · University of Texas Southwestern Medical Center · starts Nov 1, 2026
- Safety and Immunogenicity of a Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Recombinant…NCT07855172 · Phase 1 / Phase 2 · Serum Institute of India Pvt. Ltd. · starts Nov 1, 2026
- Study of BK1803 in Healthy InfantsNCT07793513 · Phase 3 · Tanabe Pharma Corporation · starts Oct 21, 2026
- Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe RegionsNCT07654283 · Phase 2 · AusperBio Therapeutics Inc. · starts Sep 1, 2026
- Phase Ⅲ Clinical Trial of an Inactivated Hepatitis A VaccineNCT07793227 · Phase 3 · Sinovac Biotech Co., Ltd · starts Aug 20, 2026
- A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and…NCT07557251 · Phase 1 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · starts Aug 12, 2026
- "HBV unIversal vs Point-Of-Care-based Antiviral treatMent to Prevent Mother-to-child Transmission"NCT07054359 · Not applicable · ANRS, Emerging Infectious Diseases · starts Aug 10, 2026
- ACT201 Injection in Healthy Participants and Participants With Chronic Hepatitis B (CHB)NCT07741461 · Phase 1 · Xiamen Amoytop Biotech Co., Ltd. · starts Aug 6, 2026
Drug Pipeline
1 approved, 5 in phase 3, 3 in phase 2, 3 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Lamivudine
- Ribavirin
- Phase 3 Inosine-5'-monophosphate dehydrogenase 1 inhibitor
- Telbivudine
- Phase 3 DNA polymerase/reverse transcriptase inhibitor
- Peginterferon ALFA-2A
- Phase 3 Interferon alpha/beta receptor agonist
- Peginterferon ALFA-2B
- Phase 3 Interferon alpha/beta receptor agonist
- Ademetionine
- Phase 3
- Pioglitazone
- Phase 2 Peroxisome proliferator-activated receptor gamma agonist
- Metformin
- Phase 2 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Fish oil triglycerides
- Phase 2 Supplement
- Acetaminophen
- Phase 1 Cyclooxygenase inhibitor
- Tenofovir disoproxil
- Phase 1 Human immunodeficiency virus type 1 reverse transcriptase inhibitor
- Bersacapavir
- Phase 1 Core antigen modulator
How Its Trials Ended
3,626 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 1,088 whose ending is known, 58% met their primary endpoint, 6% missed it and 36% stopped early.
- Completed, result not reported1,58244%
- Met its primary endpoint63117%
- Status unknown60117%
- Ongoing35510%
- Stopped: other or unclear2176%
- Stopped: enrollment or feasibility913%
- Missed its primary endpoint602%
- Stopped: sponsor or business decision401%
- Stopped: lack of efficacy231%
- Stopped: safety140%
- Stopped: funding120%
Trials Authorized in Canada
The 10 newest of 131; search them all in Canada trials| Oct 2, 2026 | A phase I, open-label, multi-center, dose escalation study to evaluate the safety, pk, and pd of azd6750 in participants with chronic hepatitis b on standard…AZD6750 | AstraZeneca Pharmaceuticals | Pending |
| Jul 22, 2026 | A phase 2 multi-center, randomized, open-label study to assess the efficacy and safety of ahb-137 in nucleos(t)ide analogue-treated participants with chronic…AHB-137 | Ausperbio Therapeutics Inc. | Pending |
| Dec 2, 2025 | A phase 2/3, randomized, double-blind, multicenter, placebo-controlled study of inebilizumab in participants with autoimmune hepatitisUplizna | Amgen | Ongoing |
| May 26, 2025 | Phase 3, randomized, controlled, open-label study to compare the efficacy and safety of bemnifosbuvir-ruzasvir fixed-dose combination (bem/rzr fdc) versus…Bemnifosbuvir (AT-527)-RUZASVIR (AT-038) | Atea Pharmaceuticals Inc | Closed |
| May 16, 2025 | A study to evaluate the efficacy and safety of steroid sparing strategy in immune related hepatitisPrednisone / dexamethasone | Cancer Care Provincial Health Corporation | Ongoing |
| May 14, 2025 | A randomized, double-blind, active-controlled multicenter phase 2 study evaluating the efficacy and safety of alg-000184 compared with tenofovir disoproxil…Pevifoscorvir sodium (ALG-000184) / tenofovir disoproxil | Aligos Therapeutics, Inc. | Ongoing |
| May 8, 2025 | A global, randomized, open-label, multicenter, phase 2b/3 trial evaluating bjt-778 vs delayed treatment for the treatment of chronic hepatitis delta infection…Brelovitug (BJT-778) | Mirum Pharmaceuticals | Ongoing |
| Mar 20, 2025 | A phase 3 randomized, open-label study to evaluate the efficacy and safety of tobevibart+elebsiran combination therapy in participants with chronic hdv…Tobevibart (VIR-3434) / elebsiran (VIR-2218) | Vir Biotechnology, Inc. | Ongoing |
| Nov 6, 2024 | A double-blind, randomized, placebo-controlled, single and multiple dose study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of…AB-101 | Arbutus Biopharma Corporation | Closed |
| Sep 23, 2024 | A phase 2b, multi-centre, randomized, partially placebo-controlled, double-blind study to investigate the safety and efficacy of sequential therapy with…Bepirovirsen (GSK3228836) / daplusiran-tomligisiran (GSK5637608/JNJ-73763989) | GSK | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 36| May 22, 2026 | HepcludexTreatment of chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis | Gilead Sciences, Inc. | Approved |
| Jan 25, 2024 | KeytrudaTreatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a… | MSD International Business GmbH | Approved |
| Jun 10, 2021 | EpclusaTreatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6… | Gilead Sciences, Inc. | Approved |
| Jun 10, 2021 | MavyretTreatment of adult and pediatric patients 3 years and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection… | AbbVie, Inc. | Approved |
| Mar 19, 2020 | EpclusaEPCLUSA is indicated for the treatment of adults and pediatric patients 6 years of age and older or weighing at least 17 kg with chronic… | Gilead Sciences, Inc. | Approved |
| Aug 28, 2019 | SovaldiSOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without… | Gilead Sciences, Inc. | Approved |
| Aug 28, 2019 | SovaldiSOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without… | Gilead Sciences, Inc. | Approved |
| Aug 28, 2019 | HarvoniHARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV)… | Gilead Sciences, Inc. | Approved |
| Aug 28, 2019 | HarvoniHARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV)… | Gilead Sciences, Inc. | Approved |
| Apr 30, 2019 | MavyretMAVYRET is indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis… | AbbVie, Inc. | Approved |
| Apr 7, 2017 | SovaldiTreatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without… | Gilead Sciences, Inc. | Approved |
| Apr 7, 2017 | HarvoniTreatment of pediatric patients 12 years of age and older or weighing at least 35 kg with chronic hepatitis C virus genotype 1, 4, 5, or 6… | Gilead Sciences, Inc. | Approved |
| Apr 6, 2007 | HepaGam BPrevention of hepatitis B recurrence following liver transplantation in HBsAG-positive liver transplant patients | Cangene Corporation | Approved |
| Jul 29, 2003 | RebetolTreatment of chronic hepatitis C among previously untreated pediatric patients at least three years of age or older. | Schering Corporation | Approved |
| Oct 21, 2026 | BrelovitugTreatment of active hepatitis delta virus infection | Mirum Pharmaceuticals, Inc. | Designated |
Medicines Authorised in the EU
Newest first; 15 of 26| Feb 18, 2021 | Heplisav BHepatitis B surface antigen | Dynavax GmbH | EMA ↗ |
| Jul 31, 2020 | HepcludexBulevirtide · orphan | Gilead Sciences Ireland UC | EMA ↗ |
| Sep 25, 2017 | Entecavir AccordEntecavir · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Sep 18, 2017 | Entecavir Viatris (previously Entecavir Mylan)Entecavir · generic | Viatris Limited | EMA ↗ |
| Jul 26, 2017 | MaviretGlecaprevir;pibrentasvir | AbbVie Deutschland GmbH & Co. KG | EMA ↗ |
| Jul 26, 2017 | VoseviSofosbuvir;velpatasvir;voxilaprevi | Gilead Sciences Ireland UC | EMA ↗ |
| Jan 9, 2017 | VemlidyTenofovir alafenamide | Gilead Sciences Ireland UC | EMA ↗ |
| Jul 22, 2016 | ZepatierElbasvir;grazoprevir | Merck Sharp & Dohme B.V. | EMA ↗ |
| Jul 6, 2016 | EpclusaSofosbuvir;velpatasvir | Gilead Sciences Ireland UC | EMA ↗ |
| Feb 15, 2016 | VaxelisDiphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed) | MCM Vaccine B.V. | EMA ↗ |
| Nov 17, 2014 | HarvoniLedispavir;sofosbuvir | Gilead Sciences Ireland UC | EMA ↗ |
| Jan 16, 2014 | SovaldiSofosbuvir | Gilead Sciences Ireland UC | EMA ↗ |
| Apr 17, 2013 | HexacimaDiphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed) | Sanofi Winthrop Industrie | EMA ↗ |
| Apr 17, 2013 | HexyonDiphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed) | Sanofi Winthrop Industrie | EMA ↗ |
| Nov 30, 2009 | ZutectraHuman hepatitis B immunoglobulin | Biotest Pharma GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA